Clinical Research Directory
Browse clinical research sites, groups, and studies.
Moderate-to-Severe Dry Eye Disease Relief Using Acoltremon
Sponsor: Colvard Kandavel Eye Center
Summary
To evaluate the impact of Acoltremon 0.003% on subjective dry eye symptoms using validated patient-reported outcome measures: Eye Dryness Score Visual Analog Scale (EDS-VAS). The primary aim is to characterize the rapidity of symptomatic relief in moderate to severe dry eye disease (DED), with attention to short-term therapy.
Official title: Acoltremon Symptom Tracking and Relief Assessment in Moderate-to-Severe Dry Eye Disease
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
OBSERVATIONAL
Enrollment
50
Start Date
2025-11-24
Completion Date
2026-10
Last Updated
2025-12-08
Healthy Volunteers
Not specified
Conditions
Interventions
Acoltremon
Patients will administer Acoltremon 0.003% as per labeled directions. Assessments with the Ocular Surface Disease Index (OSDI) will occur at Baseline, treatment at 14 days, and treatment at 28 days. Secondary endpoints include change from baseline rating scale 1-5 in severity of various symptoms of dry eye: Blurriness, eye irritation/Discomfort, Burning/Stinging, Photophobia/Pain, Sandy/gritty/Foreign Body Sensation, Fatigue/Tired Eyes).
Locations (1)
Colvard-Kandavel Eye Center
Encino, California, United States